WO2021151180A3 - Anticorpo, seu uso, composição farmacêutica o compreendendo, método de diagnóstico de infecções fúngicas, kit de diagnóstico de infecções fúngicas e método para tratamento de infecções fúngicas - Google Patents

Anticorpo, seu uso, composição farmacêutica o compreendendo, método de diagnóstico de infecções fúngicas, kit de diagnóstico de infecções fúngicas e método para tratamento de infecções fúngicas Download PDF

Info

Publication number
WO2021151180A3
WO2021151180A3 PCT/BR2021/050007 BR2021050007W WO2021151180A3 WO 2021151180 A3 WO2021151180 A3 WO 2021151180A3 BR 2021050007 W BR2021050007 W BR 2021050007W WO 2021151180 A3 WO2021151180 A3 WO 2021151180A3
Authority
WO
WIPO (PCT)
Prior art keywords
fungal infections
diagnosing
fungal
antibody
pharmaceutical composition
Prior art date
Application number
PCT/BR2021/050007
Other languages
English (en)
French (fr)
Other versions
WO2021151180A2 (pt
Inventor
Alexandre Bezerra Conde FIGUEIREDO
Marcio Lourenco RODRIGUES
Fernando de Paiva CONTE
Fernanda Lopes FONSECA
Marcia ARISSAWA
Original Assignee
Fundação Oswaldo Cruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundação Oswaldo Cruz filed Critical Fundação Oswaldo Cruz
Priority to CN202180011835.5A priority Critical patent/CN115087668A/zh
Priority to US17/796,661 priority patent/US20240262897A1/en
Priority to EP21747645.6A priority patent/EP4169939A4/en
Publication of WO2021151180A2 publication Critical patent/WO2021151180A2/pt
Publication of WO2021151180A3 publication Critical patent/WO2021151180A3/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56961—Plant cells or fungi
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

A presente invenção fornece anticorpos monoclonais contra oligômero de quitina através da técnica de hibridomas. Os referidos anticorpos podem ser utilizados como ferramentas para diagnóstico e tratamento de infecções fúngicas. Também são reveladas composições farmacêuticas e kits para tratamento de infecções fúngicas compreendendo os referidos anticorpos. Ademais são revelados ainda um método de diagnóstico de infecções fúngicas utilizando os referidos anticorpos e o seu uso na preparação de um medicamento para tratar infecções fúngicas.
PCT/BR2021/050007 2020-01-31 2021-01-12 Anticorpo, seu uso, composição farmacêutica o compreendendo, método de diagnóstico de infecções fúngicas, kit de diagnóstico de infecções fúngicas e método para tratamento de infecções fúngicas WO2021151180A2 (pt)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202180011835.5A CN115087668A (zh) 2020-01-31 2021-01-12 抗体、其用途、药物组合物，包括真菌感染诊断方法、真菌感染诊断试剂盒和真菌感染治疗方法
US17/796,661 US20240262897A1 (en) 2020-01-31 2021-01-12 Antibody, related use, pharmaceutical composition including method for diagnosing fungal infections, fungal infection diagnosis kit and method for treating fungal infections
EP21747645.6A EP4169939A4 (en) 2020-01-31 2021-01-12 ANTIBODY, ITS USE, PHARMACEUTICAL COMPOSITION COMPRISING SAME, METHOD FOR DIAGNOSING FUNGAL INFECTIONS, KIT FOR DIAGNOSING FUNGAL INFECTIONS AND METHODS FOR TREATING FUNGAL INFECTIONS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRBR102020002165-6 2020-01-31
BR102020002165-6A BR102020002165A2 (pt) 2020-01-31 2020-01-31 Anticorpo, seu uso, composição farmacêutica o compreendendo, método de diagnóstico de infecções fúngicas, kit de diagnóstico de infecções fúngicas e método para tratamento de infecções fúngicas.

Publications (2)

Publication Number Publication Date
WO2021151180A2 WO2021151180A2 (pt) 2021-08-05
WO2021151180A3 true WO2021151180A3 (pt) 2021-10-28

Family

ID=77080011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2021/050007 WO2021151180A2 (pt) 2020-01-31 2021-01-12 Anticorpo, seu uso, composição farmacêutica o compreendendo, método de diagnóstico de infecções fúngicas, kit de diagnóstico de infecções fúngicas e método para tratamento de infecções fúngicas

Country Status (5)

Country Link
US (1) US20240262897A1 (pt)
EP (1) EP4169939A4 (pt)
CN (1) CN115087668A (pt)
BR (1) BR102020002165A2 (pt)
WO (1) WO2021151180A2 (pt)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200951B1 (en) * 1998-03-12 2001-03-13 Icos Corporation Chitinase chitin-binding fragments
KR20050096499A (ko) * 2004-03-31 2005-10-06 한국식품연구원 키토산올리고당 및 키틴올리고당의 효소면역측정법

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
AU2907692A (en) * 1991-10-22 1993-05-21 Albert Einstein College Of Medicine Of Yeshiva University Antibodies to polysaccharide of c. neoformans
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5922545A (en) 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20080014192A1 (en) * 2006-05-23 2008-01-17 Poeta Maurizio D Methods For The Diagnosis And Treatment of Fungal Infections Caused By Microorganisms Producing Glucosylceramide
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200951B1 (en) * 1998-03-12 2001-03-13 Icos Corporation Chitinase chitin-binding fragments
KR20050096499A (ko) * 2004-03-31 2005-10-06 한국식품연구원 키토산올리고당 및 키틴올리고당의 효소면역측정법

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK 24 July 2016 (2016-07-24), "immunoglobulin heavy chain variable region, partial [Mus musculus", Database accession no. AA019699.1 *
DATABASE Protein 16 October 2017 (2017-10-16), "immunoglobulin light chain variable region, partial [Mus musculus", XP055864638, retrieved from NCBI Database accession no. ATI98585.1 *
DATABASE Protein 9 March 2016 (2016-03-09), "immunoglobulin kappa light chain variable region, partial [Mus musculus", XP055864641, retrieved from NCBI Database accession no. AMN89630.1 *
FONSECA FERNANDA L., NIMRICHTER LEONARDO, CORDERO RADAMES J. B., FRASES SUSANA, RODRIGUES JESSICA, GOLDMAN DAVID L., ANDRUSZKIEWIC: "Role for Chitin and Chitooligomers in the Capsular Architecture of Cryptococcus neoformans", EUKARYOTIC CELL, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 8, no. 10, 1 October 2009 (2009-10-01), US , pages 1543 - 1553, XP055864627, ISSN: 1535-9778, DOI: 10.1128/EC.00142-09 *
FONSECA FERNANDA L.; GUIMARÃES ALLAN J.; KMETZSCH LÍVIA; DUTRA FABIANNO F.; SILVA FERNANDA D.; TABORDA CARLOS P.; ARAUJO GLAUBER D: "Binding of the wheat germ lectin toCryptococcus neoformanschitooligomers affects multiple mechanisms required for fungal pathogenesis", FUNGAL GENETICS AND BIOLOGY, SAN DIEGO, CA, US, vol. 60, 19 April 2013 (2013-04-19), US , pages 64 - 73, XP028772264, ISSN: 1087-1845, DOI: 10.1016/j.fgb.2013.04.005 *
KIM, S. Y. ET AL.: "Enzyme-linked immunosorbent assay for detection of chitooligosaccharides", BIOSCI BIOTECHNOL BIOCHEM., vol. 64, no. 4, 2000, pages 696 - 701, XP055488887, DOI: 10.1271/bbb.64.696 *
M. L. RODRIGUES, L. SHI, E. BARRETO-BERGTER, L. NIMRICHTER, S. E. FARIAS, E. G. RODRIGUES, L. R. TRAVASSOS, J. D. NOSANCHUK: "Monoclonal Antibody to Fungal Glucosylceramide Protects Mice against Lethal Cryptococcus neoformans Infection", CLINICAL AND VACCINE IMMUNOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 14, no. 10, 1 October 2007 (2007-10-01), pages 1372 - 1376, XP055452645, ISSN: 1556-6811, DOI: 10.1128/CVI.00202-07 *

Also Published As

Publication number Publication date
WO2021151180A2 (pt) 2021-08-05
CN115087668A (zh) 2022-09-20
BR102020002165A2 (pt) 2021-11-30
US20240262897A1 (en) 2024-08-08
EP4169939A2 (en) 2023-04-26
EP4169939A4 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
WO2019160751A3 (en) Methods for treating cancer with anti-pd-1 antibodies
WO2021222935A3 (en) Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
KR101302764B1 (ko) 포도상구균 감염을 치료 및 예방하기 위한 팬톤-발렌타인류코시딘의 용도
WO2006113909A3 (en) Humanized anti-cd70 binding agents and uses thereof
BRPI0619357A8 (pt) Anticorpos monoclonais, composição farmacêutica, vacina, uso dos mesmos para tratamento ou prevenção de doença de alzheimer, métodos in vitro para diagnosticar e para identificar compostos apropriados para imunização de doença de alzheimer e kits
MX2021004779A (es) Anticuerpos cd47 novedosos y metodos para usarlos.
WO2006030318A3 (en) PROTECTIVE ANTI-GLUCAN ANTIBODIES WITH PREFERENCE FOR β-1,3-GLUCANS
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
WO2023288241A8 (en) Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
MX2020012309A (es) Moleculas de union a gp41 optimizadas y usos de las mismas.
WO2022170008A3 (en) Anti-il1rap antibodies
WO2007126813A3 (en) Cross-reactive monoclonal antibodies recognizing als family proteins
WO2022011110A3 (en) Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection
WO2021151180A3 (pt) Anticorpo, seu uso, composição farmacêutica o compreendendo, método de diagnóstico de infecções fúngicas, kit de diagnóstico de infecções fúngicas e método para tratamento de infecções fúngicas
WO2021079002A3 (en) Novel antibodies for neural repair and treatment of stroke
WO2022006219A3 (en) Vhh polypeptides that bind to clostridium difficile toxin b and methods of use thereof
WO2021067628A3 (en) Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cells
WO2004110365A3 (en) Liver related disease compositions and methods
WO2023147584A3 (en) Compositions and methods for treating sialidosis
WO2023169896A8 (en) BINDING MOLECULES AGAINST FRα
WO2018236781A3 (en) Targeted therapeutics
WO2024173865A3 (en) Anti-tl1a antibody compositions and methods of treatment in the kidney
WO2024186859A3 (en) Anti-tl1a antibody compositions and methods of treatment for sarcoidosis
CA3242280A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody

Legal Events

Date Code Title Description
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21747645

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021747645

Country of ref document: EP

Effective date: 20220831